Long-term efficacy of levetiracetam for partial seizures

Seizure

Volumn 14, Issue 8, 2005, Pages 577-585

  Abou Khalil, Bassel ^a   Schaich, Lynn ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UCB   (United States)

Author keywords

Antiepileptic drugs; Epilepsy; Levetiracetam; Long term therapy; Partial seizures

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; ETHOTOIN; ETIRACETAM; GABAPENTIN; GAMMA GLUTAMYLTRANSFERASE; LAMOTRIGINE; MESUXIMIDE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONVULSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOCAL EPILEPSY; FOLLOW UP; HEADACHE; HUMAN; INFECTION; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PAIN; PRIORITY JOURNAL; PROBABILITY; SEIZURE; SIDE EFFECT; SOMNOLENCE;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DEMOGRAPHY; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PIRACETAM; TIME; TIME FACTORS; TREATMENT OUTCOME;

EID: 28944454399     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2005.09.003     Document Type: Article

References (12)

1. C.A. Hovinga Levetiracetam: A novel antiepileptic drug Pharmacotherapy 21 2001 1375-1388
2. T.E. Welty B.E. Gidal D.M. Ficker M.D. Privitera Levetiracetam: A different approach to the pharmacotherapy of epilepsy Ann Pharmacother 36 2002 296-304
3. E. Ben-Menachem U. Falter for the European Levetiracetam Study Group Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy Epilepsia 41 2000 1276-1283
4. J.J. Cereghino V. Biton B. Abou-Khalil F. Dreifuss L.J. Gauer I. Leppik and the United States Levetiracetam Study Group Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial Neurology 55 2000 236-242
5. S.D. Shorvon A. Löwenthal D. Janz E. Bielen P. Loiseau for the European Levetiracetam Study Group Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures Epilepsia 41 2000 1179-1186
6. T. Betts T. Waegemans P. Crawford A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy Seizure 9 2000 80-87
7. -1 in adult patients with refractory epilepsy Seizure 12 2003 141-149
8. Department of Health and Human Services, Food and Drug Administration Coding symbols for thesaurus of adverse reaction terms 5th ed. 1993 FDA Rockville, Maryland
9. Commission on Classification and Terminology of the International League Against Epilepsy Proposal for revised classification of epilepsies and epileptic syndromes Epilepsia 30 1989 389-399
10. E. Ben-Menachem P. Edrich B. Van Vleymen J.W.A.S. Sander B. Schmidt Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy Epilepsy Res 53 2003 57-64
11. E. Ben-Menachem E. Gilland Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy Seizure 12 2003 131-135
12. J.M. Nicolas P. Collart B. Gerin G. Mather W. Grager R. Levy et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic drug Drug Metab Dispos 27 1999 250-254